Skip to main content

View Patient Site
Full Prescribing Info
Important Safety Info
Instructions for Use
Customer Care: (855) 971-8346 (VEIN)

How it works
Patient experience
Support
Coverage updates

Clinical evidence

See the highlights from Varithena clinical studies and real-world outcomes.
See all clinical studies

Patient experience

Coverage updates

View Patient Site
Full Prescribing Info
Important Safety Info
Instructions for Use
Customer Care: (855) 971-8346 (VEIN)

Site map

HCPs: Discover Varithena’s Innovative Vein Treatment | Varithena™
Clinical Evidence: Validating efficacy and safety | Varithena™
Exploring patient experiences and outcomes | Varithena™
- Case Study: Understanding Patient Experience | Varithena™
Comprehensive support: Enhance your practice | Varithena™
Understanding indications and safety guidelines | Varithena™
How It Works: Understanding the treatment process | Varithena™

Indications

Varithena (polidocanol injectable foam) 1% is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

Important safety information

The use of Varithena is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately. Varithena can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis. Physicians administering Varithena must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease, and be trained in the administration of Varithena.

For full prescribing information visit Varithena.com.

Varithena is a registered trademark of Boston Scientific. All other trademarks are property of their respective owners.
PI-1263705-AA

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.

About Varithena

Download patient brochure

Varithena customer care

©2025 Boston Scientific Corporation or its affiliates. All rights reserved. All trademarks are property of their respective owners.

Privacy
Terms of Use
Copyright Notice
Sitemap
Contact Us
Do not sell or share my personal information